ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature

Extracorporeal Membrane Oxygenation (ECMO) has evolved as a treatment option for patients having potentially reversible severe respiratory failure who are deteriorating on conventional ventilation. During ECMO, systemic anticoagulation is needed to maintain patency of the circuit. Therefore, ongoi...

Full description

Bibliographic Details
Main Authors: Gautam Rawal, Raj Kumar, Sankalp Yadav
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2016-06-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://jcdr.net/articles/PDF/7969/20649_CE[Ra1]_F(GH)_PF1(SWAK)_PFA(AK)_PF2(PAG).pdf
id doaj-71f055341f7a4ec39a12f9b90dd7d89d
record_format Article
spelling doaj-71f055341f7a4ec39a12f9b90dd7d89d2020-11-25T03:22:56ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2016-06-01106OD10OD1110.7860/JCDR/2016/20649.7969ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of LiteratureGautam Rawal0Raj Kumar1Sankalp Yadav2Attending Consultant, Department of Respiratory Intensive Care, Max Super Specialty Hospital, Saket, New Delhi, India.Senior Consultant and Incharge, Department of Respiratory Intensive Care, Max Super Specialty Hospital, Saket, New Delhi, India.General Duty Medical Officer-II, Department of Medicine & TB, Chest Clinic Moti Nagar, North Delhi Municipal Corporation, New Delhi, India.Extracorporeal Membrane Oxygenation (ECMO) has evolved as a treatment option for patients having potentially reversible severe respiratory failure who are deteriorating on conventional ventilation. During ECMO, systemic anticoagulation is needed to maintain patency of the circuit. Therefore, ongoing haemorrhage remains a relative contra-indication to ECMO as it can further increase the bleeding. There is only limited evidence available for the use of ECMO in patients with alveolar haemorrhage. Most of these patients did not receive any anticoagulation during ECMO. We describe our experience with a patient who received intravenous anticoagulation during ECMO for refractory hypoxemic respiratory failure due to Diffuse Alveolar Haemorrhage (DAH) associated with Granulomatosis polyangitis (Wegner’s GPA). ECMO sustained life by maintaining gas exchange support and provided the time for the immunotherapy to be effective. We report the successful use of anticoagulation during ECMO in a patient with DAH.https://jcdr.net/articles/PDF/7969/20649_CE[Ra1]_F(GH)_PF1(SWAK)_PFA(AK)_PF2(PAG).pdfextracorporeal membrane oxygenationgranulomatosis polyangiitishaemoptysissystemic anticoagulation
collection DOAJ
language English
format Article
sources DOAJ
author Gautam Rawal
Raj Kumar
Sankalp Yadav
spellingShingle Gautam Rawal
Raj Kumar
Sankalp Yadav
ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
Journal of Clinical and Diagnostic Research
extracorporeal membrane oxygenation
granulomatosis polyangiitis
haemoptysis
systemic anticoagulation
author_facet Gautam Rawal
Raj Kumar
Sankalp Yadav
author_sort Gautam Rawal
title ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
title_short ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
title_full ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
title_fullStr ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
title_full_unstemmed ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature
title_sort ecmo rescue therapy in diffuse alveolar haemorrhage: a case report with review of literature
publisher JCDR Research and Publications Private Limited
series Journal of Clinical and Diagnostic Research
issn 2249-782X
0973-709X
publishDate 2016-06-01
description Extracorporeal Membrane Oxygenation (ECMO) has evolved as a treatment option for patients having potentially reversible severe respiratory failure who are deteriorating on conventional ventilation. During ECMO, systemic anticoagulation is needed to maintain patency of the circuit. Therefore, ongoing haemorrhage remains a relative contra-indication to ECMO as it can further increase the bleeding. There is only limited evidence available for the use of ECMO in patients with alveolar haemorrhage. Most of these patients did not receive any anticoagulation during ECMO. We describe our experience with a patient who received intravenous anticoagulation during ECMO for refractory hypoxemic respiratory failure due to Diffuse Alveolar Haemorrhage (DAH) associated with Granulomatosis polyangitis (Wegner’s GPA). ECMO sustained life by maintaining gas exchange support and provided the time for the immunotherapy to be effective. We report the successful use of anticoagulation during ECMO in a patient with DAH.
topic extracorporeal membrane oxygenation
granulomatosis polyangiitis
haemoptysis
systemic anticoagulation
url https://jcdr.net/articles/PDF/7969/20649_CE[Ra1]_F(GH)_PF1(SWAK)_PFA(AK)_PF2(PAG).pdf
work_keys_str_mv AT gautamrawal ecmorescuetherapyindiffusealveolarhaemorrhageacasereportwithreviewofliterature
AT rajkumar ecmorescuetherapyindiffusealveolarhaemorrhageacasereportwithreviewofliterature
AT sankalpyadav ecmorescuetherapyindiffusealveolarhaemorrhageacasereportwithreviewofliterature
_version_ 1724608690925862912